SecurityLSE:81HS / NATIONAL WESTMINSTER BANK
Institutional Owners0

Institutional Stock Ownership and Shareholders()

NATIONAL WESTMINSTER BANK (LSE:81HS) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
NATIONAL WESTMINSTER BANK (LSE:81HS) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Important Note!
Note: We do not currently have a CUSIP on file for this security. That means we are unable to search institutional fund filings (13F's) for this company, which means there may be institutional holders that we are unaware of. If you know the CUSIP or would like us to research and update this security, please let us know by leaving a message in the Welcome Group.
File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)

Related Articles

ADAP: Adaptimmune Therapeutics Analysis and Research Report

2h - Asif

Overview Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors. The company's comprehensive and proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”), and produce therapeutic candidates for administration to patients. Using its affinity engineered TCRs, the company aim to become a fully integrated cell therapy company and to be the first company to have a TCR T-cell approved for a solid tumor indication. Adaptimmune Therapeutics has four SPEAR T-cells in clinical trials, MAGE-A10, MAGE-A4, AFP and NY-ESO. Phase 1/2 clinical trials are ongoing in patients with various cancer tumor types including urothelial, melanoma, head and neck, ovarian, esophageal, gastric, multiple myeloma, hepatocellular cancers and in synovial sarcoma, myxoid round cell liposarcoma...

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

Related News Stories

The financial cost of raising a child

2018-06-21 nzherald.co.nz
The cost of raising a child from birth to 18 years old will set you back about $285,000, or around $16,000 a year.

Myanmar president nominates Deloitte partner as new finance minister

2018-05-28 reuters
YANGON (Reuters) - Myanmar’s president on Monday nominated 80-year-old Soe Win, a well-known financial professional, as the next finance minister after the previous one resigned, amid reports he was being investigated over graft accusations.

Two more Fortis directors quit ahead of crucial EGM tomorrow

2018-05-21 livemint
New Delhi: Fortis Healthcare Ltd on Monday said that its two more directors, Harpal Singh and Sabina Vaisoha, have resigned—a day ahead of a crucial meeting of shareholders called to vote on the removal of four directors of the cash-strapped healthcare chain. (6-0)

Four directors ask Fortis shareholders to take ‘informed’ decision on voting-out resolution

2018-05-09 thehindubusinessline
Our Bureau Four directors of Fortis Healthcare, whose removal was sought by two minority shareholders of the company last month, have written to all shareholders asking them to take an ‘informed decision’ while voting on the matter. (6-0)

Fortis directors ask shareholders to judiciously decide on their fate

2018-05-09 thehindubusinessline
The directors, Brian Tempest, Harpal Singh, Sabina Vaisoha and Tejinder Singh Shergill, through extensive explanations, tried to refute allegations that they had not satisfactorily exercised their respective fiduciary duties towards all shareholders and had failed to maintain the expected levels of corporate governance.